Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.53
-0.0450-1.75%
Volume:3.32M
Turnover:8.39M
Market Cap:2.39B
PE:-5.16
High:2.58
Open:2.56
Low:2.49
Close:2.57
52wk High:7.48
52wk Low:1.83
Shares:945.25M
Float Shares:194.00M
Volume Ratio:1.33
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4893
EPS(LYR):-0.5931
ROE:78.05%
ROA:-42.14%
PB:-4.18
PE(LYR):-4.26

Loading ...

Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer

Stock Track
·
Aug 11

Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer

Stock Track
·
Aug 11

Immunitybio Announces Houston’s Michael E. Debakey Va Medical Center Is Among the First Va Hospitals to Administer Anktiva® to Bladder Cancer Patients

THOMSON REUTERS
·
Aug 11

ImmunityBio Inc. Faces Securities Fraud Class Action and Shareholder Derivative Litigation Settlement

Reuters
·
Aug 09

Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.10 a Share, vs. FactSet Est of $0.11 Loss

MT Newswires Live
·
Aug 05

ImmunityBio Inc. Reports 60% Revenue Increase in Q2 2025, Reduces Net Loss to $222.2 Million

Reuters
·
Aug 05

Immunitybio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code

THOMSON REUTERS
·
Aug 05

ImmunityBio Reports Q2 Preliminary Revenue

MT Newswires Live
·
Jul 25

ImmunityBio Announces $80 Million Equity Financing from Institutional Investors in Direct Offering

Reuters
·
Jul 25

Immunitybio, Inc. Announces Execution of $80 Million Equity Financing From Multiple Institutional Investors

THOMSON REUTERS
·
Jul 25

Immunitybio Inc - Warrants Could Add $96 Mln in Proceeds

THOMSON REUTERS
·
Jul 25

ImmunityBio Reports 60% Revenue Increase in Q2 2025, Totaling $26.4 Million, Driven by ANKTIVA Unit Growth

Reuters
·
Jul 25

Immunitybio Reports 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code With Regulatory Updates

THOMSON REUTERS
·
Jul 25

Immunitybio Inc - Q2 2025 Revenue $26.4 Mln

THOMSON REUTERS
·
Jul 25

Immunitybio Inc - UK Mhra Approves Marketing Authorization Application of Anktiva

THOMSON REUTERS
·
Jul 25

Los Angeles Times to go public, owner Soon-Shiong says

Reuters
·
Jul 22

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jul 08

UK MHRA Grants Marketing Authorization for ImmunityBio's ANKTIVA Plus BCG for Bladder Cancer Treatment

Reuters
·
Jul 08

BRIEF-UK's MHRA Approves Nogapendekin Alfa Inbakicept To Treat Patients With A Type Of Bladder Cancer

Reuters
·
Jul 04

ImmunityBio Inc. Conducted Annual Meeting of Stockholders

Reuters
·
Jun 21